Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  PuriCore plc    PURI   GB00B3XBCR18

Delayed Quote. Delayed  - 02/09 11:35:25 am
23.5 GBp   -6.00%
05:49a PURICORE : stronger Biopharmaceutical company PuriCore
02/08 PURICORE : Mulls Supermarket Retail Unit Sale As It Switches Focus
02/08 PURICORE : Strategic Review and Trading Update
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

PuriCore plc : PuriCore Raises $3.5 Million

01/03/2012 | 03:11pm US/Eastern
PuriCore plc ("PuriCore" or the "Company" or the "Group") PuriCore Raises $3.5 Million MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 January 2012 - PuriCore (LSE: PURI), the water- based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that it closed on a new $3.5 million debt facility with Republic Bank on 29 December 2011. The debt will be utilized to finance the working capital requirements associated with Sterilox Fresh and FloraFresh System installations in H1 2012. The facility is structured as a promissory note with an imputed interest rate of 4%. Enquiries:

FTI Consulting Susan Quigley Ben Brewerton

+44 (0) 20 7831 3113

About PuriCore

PuriCoreplc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

1

React to this article
Latest news on PURICORE PLC
05:49a PURICORE : stronger Biopharmaceutical company PuriCore
02/08 PURICORE : Mulls Supermarket Retail Unit Sale As It Switches Focus
02/08 PURICORE : Strategic Review and Trading Update
2015 PURICORE : Director Dealing
2015 PURICORE : Non-Executive Buys Shares (DIRECTOR DEALINGS)
2015 PURICORE : Director Dealings
2015 PURICORE : Chairman Doubles Holding (DIRECTOR DEALINGS)
2015 PURICORE : Loss Widens On Gross Margin Hit And Investments, But Sales Up
2015 PURICORE : Blocklisting Interim Review
2015 PURICORE : Change of Registered Office
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials